SRRK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Scholar Rock Holding Corp (SRRK) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock shows strong potential due to its leading position in the SMA therapy market, positive analyst sentiment, and upcoming FDA approval prospects. Despite short-term volatility, the long-term growth potential outweighs risks.
The technical indicators are bullish. The MACD histogram is positive and expanding, moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading near its resistance level (R1: 46.574). RSI is neutral at 53.808, suggesting no overbought or oversold conditions.
Analysts expect apitegromab to dominate the SMA therapy market with multi-billion dollar potential.
Positive price target revisions from multiple firms, including JPMorgan, BMO Capital, and Piper Sandler, reflecting confidence in the company's growth prospects.
FDA approval expected in 2026, with a strong launch anticipated.
Short-term stock trend analysis indicates potential negative returns in the next week (-4.07%) and month (-9.88%).
No significant hedge fund or insider trading activity, indicating neutral sentiment from key stakeholders.
In Q4 2025, the company showed improvement in net income (-$90.97M, up 36.88% YoY) and EPS (-$0.75, up 22.95% YoY). However, revenue and gross margin remain at zero, reflecting the pre-revenue nature of the company as it focuses on drug development.
Analysts are highly bullish on SRRK, with multiple firms raising price targets (e.g., JPMorgan to $50, BMO Capital to $70, Piper Sandler to $58). The consensus is that apitegromab has blockbuster potential, and its approval and launch are on track for 2026.
